Recent Partnerships Boehringer Ingelheim has entered into recent partnerships with Salipro Biotech AB and software firm Veeva Systems, indicating potential collaboration opportunities and increased market reach.
Innovative Technology Platforms The launch of the One Medicine platform and unified cloud platform demonstrates Boehringer Ingelheim's commitment to leveraging cutting-edge technology for streamlining product development, suggesting possible technology integration sales.
Focus on Advanced Therapies Boehringer Ingelheim's development of advanced therapies for sensorineural conditions presents a niche market opportunity for companies specializing in related treatment areas.
Market Recognition Being recognized as a top employer in the Philippines for seven consecutive years showcases Boehringer Ingelheim's strong brand reputation, potentially opening doors for partnerships with companies seeking similar recognition.
Potential Growth via CKD Initiative The launch of the Chronic Kidney Disease (CKD) initiative indicates Boehringer Ingelheim's focus on addressing health inequalities, presenting sales opportunities for providers of solutions or services in the kidney health sector.
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1B
$1BBoehringer Ingelheim uses 8 technology products and services including Adobe Target, MATLAB, NumPy, and more. Explore Boehringer Ingelheim's tech stack below.
| Boehringer Ingelheim Email Formats | Percentage |
| First.Last@boehringer-ingelheim.com | 96% |
| Last.First@boehringer-ingelheim.com | 2% |
| First.Middle@boehringer-ingelheim.com | 1% |
| FirstLast@boehringer-ingelheim.com | 1% |
| FLast@rdg.boehringer-ingelheim.com | 59% |
| Last@rdg.boehringer-ingelheim.com | 32% |
| Last.First@rdg.boehringer-ingelheim.com | 2% |
| First.Last@rdg.boehringer-ingelheim.com | 2% |
| First_L@rdg.boehringer-ingelheim.com | 1% |
| Last_First@rdg.boehringer-ingelheim.com | 1% |
| First_Last@rdg.boehringer-ingelheim.com | 1% |
| LastFirst@rdg.boehringer-ingelheim.com | 1% |
| LFirst@rdg.boehringer-ingelheim.com | 1% |
| FLast@bi-vetmedica.com | 79% |
| First.Last@bi-vetmedica.com | 11% |
| FirstL@bi-vetmedica.com | 6% |
| LastF@bi-vetmedica.com | 1% |
| LF@bi-vetmedica.com | 1% |
| First-L@bi-vetmedica.com | 1% |
| Last.First@bi-vetmedica.com | 1% |
Pharmaceutical ManufacturingGermany10001+ Employees
Our people are our strength. And, together with over 54,000 colleagues, we're creating the next breakthrough in the world of health and innovation for both humans and animals. Are you ready to join us? #LifeForward Privacy Notice: https://www.boehringer-ingelheim.com/privacy-notice Imprint: https://www.boehringer-ingelheim.com/imprint
Company Overview
Funding & FinancialsBoehringer Ingelheim's revenue is in the range of $1B
Funding & FinancialsBoehringer Ingelheim's revenue is in the range of $1B
1-888-653-2347 
support@leadiq.com